MedTrace Logo

A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

NCT00109278 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1100

Last updated 2017-03-15

No results posted yet for this study

Summary

The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

Conditions

Interventions

BIOLOGICAL

V205C, measles, mumps, and rubella virus vaccine live

BIOLOGICAL

Comparator: Measles, Mumps, and Rubella Virus Vaccine Live

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2005-05-31
Completion
2005-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109278 on ClinicalTrials.gov